Journal of Chemotherapy

Papers
(The H4-Index of Journal of Chemotherapy is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Ceftobiprole and daptomycin concentrations in valve tissue in a patient with mitralic native valve endocarditis24
MiR-302a-3p reduces cisplatin resistance of esophageal squamous cell carcinoma cells by targeting EphA224
Comparative effectiveness of chemotherapy in different histological types of pancreatic cancer: a PSM-based study using the SEER database23
Comparative in vitro activities of eravacycline in combination with colistin, meropenem, or ceftazidime against various Achromobacter spp. strains isolated from patients with cystic fibrosis21
Efficacy and safety of intravenous fosfomycin for the treatment of carbapenem-resistant Klebsiella pneumoniae17
Piperacillin/Tazobactam is associated with a higher risk of acute kidney injury compared to cefepime and meropenem17
YAP/TAZ axis was involved in the effects of metformin on breast cancer15
Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients13
Enzalutamide combination with Arsenic trioxide suppresses the progression of castration-resistant prostate cancer13
Optimization of the vancomycin administration regimen by clinical pharmacists based on a population pharmacokinetics model: a prospective interventional study12
Looking for Stenotrophomonas maltophilia treatment: in vitro activity of ceftazidime/avibactam alone and in combination with aztreonam12
The use of antiviral drugs in children11
Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma11
Underutilisation of prophylactic G-CSF in breast cancer patients receiving adjuvant docetaxel/cyclophosphamide chemotherapy11
Nivolumab-induced Lambert-Eaton myasthenic syndrome: an immune-related adverse event in nonsmall cell lung cancer11
0.049520969390869